Telix Pharmaceuticals Limited (TLX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.14B
Last updated: Nov 17, 2026 at 11:05 AM ET
Telix Pharmaceuticals Limited (TLX) Financials: Revenue, Profit and Cash Flow
Telix Pharmaceuticals reported revenue of AUD 789.77M for the fiscal year ended Dec 31, 2025, up 0.8% from the year before. That year, operating cash flow was AUD -16.99M and free cash flow was AUD -54.25M. The quarter ended Jun 30, 2026 had revenue of AUD 476.04M and net income of AUD 38.22M.
Revenue and Margins
The operating margin was 2.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from AUD 29.40M, a compound annual rate of 44.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 789.77M | +0.8% | 53.1% | 2.2% | N/A |
| Dec 2024 | 783.21M | +55.8% | 65.1% | 10.5% | 6.4% |
| Dec 2023 | 502.55M | +213.9% | 62.6% | 3.2% | 1.0% |
| Dec 2022 | 160.10M | +2007.6% | 59.3% | -57.4% | -65.0% |
| Dec 2021 | 7.60M | +45.7% | 66.5% | -1069.6% | -1059.9% |
| Dec 2020 | 5.21M | +49.6% | 61.2% | -847.7% | -861.1% |
| Dec 2019 | 3.48M | +1685.9% | -340.7% | -1033.6% | -799.6% |
| Dec 2018 | 195.14K | -99.4% | 100.0% | -15016.1% | -7087.1% |
| Dec 2017 | 31.77M | +8.0% | 0.0% | -20.5% | -20.1% |
| Dec 2016 | 29.40M | N/A | N/A | -0.1% | -0.1% |
Income Statement
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 789.77M | 783.21M | 502.55M | 160.10M | 7.60M | 5.21M | 3.48M | 195.14K | 31.77M | 29.40M |
| Cost of revenue | 370.31M | 273.53M | 188.16M | 65.17M | 38.68M | 2.02M | 15.36M | 16.08M | 3.79K | 21.35M |
| Gross profit | 419.47M | 509.68M | 314.39M | 94.93M | 5.05M | 3.19M | -11.88M | 195.14K | -3.79K | N/A |
| Research and development | 168.26M | 121.03M | 128.84M | 57.86M | 34.13M | 23.09M | 21.16M | 18.69M | 2.98M | 10.00K |
| Operating income | 17.46M | 82.13M | 15.84M | -91.93M | -81.25M | -44.19M | -36.02M | -29.30M | -6.52M | -30.00K |
| Net income | N/A | 49.92M | 5.21M | -104.08M | -80.51M | -44.89M | -27.87M | -13.83M | -6.38M | -44.00K |
| EBITDA | 52.30M | 100.57M | 22.97M | N/A | -70.07M | N/A | -24.48M | -29.30M | -5.68M | -14.00K |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 476.04M | 410.04M | 355.14M | 594.24M | 188.96M | 281.71M | 220.83M | 136.05M | 24.05M | 4.69M | 2.91M | 3.61M |
| Gross profit | 245.55M | 216.39M | 172.65M | 385.80M | 123.88M | 223.97M | 90.81M | 44.89M | -15.57M | -18.86M | -11.18M | -8.25M |
| Operating income | -13.71M | 6.49M | 9.45M | 68.38M | 13.75M | -15.60M | 31.44M | -9.70M | -63.49M | -49.92M | -31.60M | -29.14M |
| Net income | 38.22M | -4.79M | -2.09M | 38.24M | 11.68M | 19.53M | -14.32M | -33.19M | -70.89M | -48.00M | -32.51M | -26.59M |
Balance Sheet
As of Dec 2025, total debt of AUD 410.57M exceeded cash and equivalents by 268.75M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.18B | 1.52B | 398.30M | 255.35M | 109.81M | 157.82M | 102.61M | 76.71M | 51.09M | 18.61M |
| Current assets | 330.18M | 918.56M | 224.85M | 173.23M | 47.54M | 93.63M | 58.68M | 35.86M | 49.55M | N/A |
| Cash and equivalents | 141.82M | 710.35M | 123.24M | 116.33M | 22.04M | 77.94M | 44.60M | 25.77M | 48.76M | N/A |
| Total liabilities | 766.49M | 948.22M | 249.39M | 175.35M | 106.17M | 78.81M | 32.53M | 23.80M | 1.80M | 20.38M |
| Short-term debt | 18.65M | 21.49M | 1.56M | 1.28M | 632.00K | 767.00K | 490.00K | 1.13M | 345.43K | N/A |
| Long-term debt | 391.91M | 551.82M | 8.21M | 3.31M | N/A | 95.00K | N/A | N/A | N/A | N/A |
| Shareholder equity | 415.24M | 568.21M | 148.91M | 80.01M | 2.16M | 79.02M | 70.08M | 52.90M | 49.29M | -1.77M |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.36B | 1.18B | 1.20B | 1.52B | 745.96M | 398.30M | 310.34M | 255.35M | 215.94M | 109.81M | 128.84M | 157.82M |
| Total liabilities | 873.85M | 766.49M | 772.03M | 948.22M | 341.98M | 249.39M | 234.28M | 175.35M | 110.53M | 107.66M | 80.91M | 78.81M |
| Cash and equivalents | 251.82M | 141.82M | 208.24M | 710.35M | 118.84M | 123.24M | 131.73M | 116.33M | 122.61M | 22.04M | 49.62M | 77.94M |
| Shareholder equity | 487.49M | 415.24M | 421.94M | 568.21M | 403.97M | 148.91M | 76.06M | 80.01M | 105.41M | 2.16M | 47.93M | 79.02M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -16.99M | 43.03M | 23.88M | -63.97M | -59.33M | 1.96M | -23.33M | -20.75M | -6.03M | N/A |
| Capital expenditures | 37.25M | 14.32M | 9.68M | 7.04M | 1.34M | 248.00K | 403.00K | 198.73K | 5.64K | N/A |
| Free cash flow | -54.25M | 28.71M | 14.21M | -71.01M | -60.67M | 1.71M | -23.74M | -20.95M | -6.04M | N/A |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 54.79M | N/A |
| Investing cash flow | -280.93M | -135.17M | -25.49M | -17.00M | -2.73M | -1.09M | -468.00K | -2.69M | -1.26K | N/A |
| Financing cash flow | -3.65M | 638.92M | 10.19M | 174.96M | 2.85M | 34.12M | 42.72M | -869.00K | 54.79M | N/A |
Quarterly
| Line item | Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 22.97M | -34.73M | 16.15M | 3.95M | 34.98M | 10.63M | 13.26M | -3.75M |
| Capital expenditures | 18.91M | 26.47M | 6.07M | 9.63M | 4.60M | 6.67M | 3.01M | 4.66M |
| Free cash flow | 4.06M | -61.20M | 10.08M | -5.68M | 30.38M | 3.96M | 10.25M | -8.41M |
Frequently Asked Questions About TLX
What is Telix Pharmaceuticals' annual revenue?
Telix Pharmaceuticals reported revenue of AUD 789.77M for the fiscal year ended Dec 31, 2025.
How fast is Telix Pharmaceuticals' revenue growing?
Revenue was up 0.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 70.2%.
How much free cash flow does TLX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of AUD -16.99M minus capital expenditures of AUD 37.25M produced free cash flow of AUD -54.25M.
How much debt does Telix Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of AUD 391.91M, short-term debt of AUD 18.65M and cash and equivalents of AUD 141.82M.
What is TLX's profit margin?
For the fiscal year ended Dec 31, 2025, Telix Pharmaceuticals reported gross margin of 53.1% and operating margin of 2.2%.
TLX pages: Overview, Financials